Protheragen, Inc. and Quarkmed have officially signed a strategic cooperation agreement. Under the agreement, Protheragen will leverage its global innovative drug incubation network and cross-border BD channel advantages to continuously introduce high-quality overseas client resources and project opportunities to Quarkmed, supporting Quarkmed in further expanding its international business presence.
Against the backdrop of accelerating cross-border flows of global pharmaceutical innovation, the strategic partnership between Protheragen and Quarkmed is designed to deeply connect Protheragen’s long-established overseas project sources and client networks with Quarkmed’s professional clinical CRO capabilities, enabling efficient cross-border resource conversion.
Protheragen, headquartered in New York, USA, is a global pharmaceutical R&D incubation and cross-border BD enablement platform. Its business covers three core areas: cross-border BD consulting, project incubation, and equity investment. With over 18 years of industry experience and an extensive cooperation network of overseas pharmaceutical companies and biotech firms, Protheragen possesses unique advantages in cross-border deal facilitation, project financing, and in/out-licensing, continuously bridging global innovative drug projects with Chinese service resources.
Quarkmed, founded in 2011, is a professional clinical CRO service company. Headquartered in Beijing, with branches and offices in Shanghai, Guangzhou, Hangzhou, Chengdu, Wuhan, Zhengzhou, Shenyang, and other cities, Quarkmed’s services cover comprehensive business segments including pharmaceutical and medical device clinical research, data management and statistical analysis, and SMO, as well as international registration services for markets such as Europe, Australia, and North America. Quarkmed has deep expertise in nuclear medicine, oncology, CNS, cell and gene therapy, cardiovascular and cerebrovascular diseases, respiratory diseases, and other areas, with particularly industry-leading specialization in radiopharmaceutical clinical research.
On the technical capability front, Quarkmed’s Nuclear Medicine Division possesses extensive experience spanning from regulatory registration to clinical operations, providing comprehensive services for radiopharmaceuticals, radiotherapy and imaging, and isotope tracer products, including regulatory registration, clinical operations, and commercialization enablement. The company’s radiopharmaceutical clinical capabilities have been extended into frontier areas such as CNS and cell and gene therapy, achieving synergistic effects across multiple therapeutic domains. Furthermore, Quarkmed actively participates in industry ecosystem development, serving as a governing unit member of the Radiopharmaceutical Division of the Chinese Nuclear Society, and co-founding both the VIQU Nuclear Medicine CXO Alliance and the DIA Radiopharmaceutical Academic Community, continuously exerting influence in industry standard-setting and technological innovation.
Under the agreement, Protheragen will utilize its global BD network to precisely match Quarkmed with overseas pharmaceutical companies, biotech firms, and research institutions, guiding more international clients to conduct their clinical research projects through Quarkmed. Notably, Quarkmed’s deep expertise and clinical operational excellence in radiopharmaceuticals (nuclear medicine) will play a critical role in helping Protheragen and its overseas clients navigate the high-barrier challenges of radiopharmaceutical clinical research – including specialized logistics for radiopharmaceuticals, radiation safety management, coordination of nuclear medicine wards, and China-US dual filing requirements. In addition, Protheragen will provide value-added services such as cross-border project financing matchmaking and international business development support to help Quarkmed continuously enhance its global presence. Quarkmed, in turn, will rely on its professional full-process clinical research operation capabilities, China-US dual filing experience, and deep expertise in nuclear medicine to deliver high-quality, compliant clinical CRO services to the overseas clients introduced by Protheragen.
The partnership organically couples Protheragen’s global overseas resource network with Quarkmed’s cutting-edge expertise in nuclear medicine. Not only does this help Quarkmed gain more international clients and project opportunities while accelerating its pace of international expansion, but it also provides Protheragen and its overseas clients with strong local support for executing radiopharmaceutical clinical research projects in China. Together, the two parties aim to build an open, pragmatic new channel for cross-border pharmaceutical collaboration.
Protheragen's business is growing rapidly after founded in New York. Our business has evolved from the initial cross-border BD consulting service to encompass segments in equity investment and project incubation.
 |
Protheragen Inc. |
 |
Quick Links |
